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Purpose or Objective: To evaluate the efficacy and safety of 
stereotactic radiation therapy (SRT) in the treatment of 
patients with recurrent pancreatic adnocarcinoma at the 
stump or abdominal lymph node after surgery. 
 
Material and Methods: Between October 1 2011 and May1 
2015, patients with recurrent pancreatic adnocarcinoma at 
the stump or abdominal lymph nodes after surgery were 
enrolled and treated with SRT at our hospital. The primary 
end-point was overall survival after SRT (OS). Secondary end-
points were: local control rates (LC), time to symptom 
alleviation, and toxicity using the Common Terminology 
Criteria for Adverse Events (CTCAE v4.0). 
 
Results: Twenty-four patients with 24 lesions (17 abdominal 
lymph nodes and 7 stumps) were treated with SRT. Among 
these patients, five patients were presented with abdominal 
lymph node and synchronous metastases in liver and lung. For 
the entire cohort, the median OS from diagnosis and SRT 
were 28.93 months and 12.20 months, respectively. The 6-
month, 12-month, and 24-month actuarial LC rates were 95.2 
%, 83.8% and 62.1% respectively. Symptom alleviation was 
observed in 11 of 14 patients reported symptoms (78.6%) with 
a median of 8 days (range, 1-14 days) after SRT. Nine 
patients (37.5%) experienced CTCAE v4.0 Grade 1 to 2 acute 
toxicities; one patient experienced grade 3 acute toxicity due 
to thrombocytopenia. 
 
Conclusion: SRT is a safe and efficacious treatment modality 
for patients with recurrent pancreatic adnocarcinoma at the 
stump or abdominal lymph nodes after surgery. Further 
studies are needed before SRT can be recommended 
routinely. 
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Purpose or Objective: Based on the results of the 
intergroup-0123/RTOG 94-05 trial that demonstrated no 
benefit of dose escalation over 50.4 Gy in definitive 
chemoradiotherapy (CRT) for esophageal carcinoma, 50.4 Gy 
appears to be accepted as a standard dose. Radiobiologically, 
however, higher radiation doses, if safely delivered, could 
lead to better local control. We have used combination of 
standard FP (5-fluorouracil [5-FU] and cisplatin) 
chemotherapy and radiation with doses ≥60 Gy in the 
treatment of non-metastatic esophageal cancer. We report 
clinical outcome of the treatment protocol. 
 
Material and Methods: Between 2002 and 2014, 86 patients 
with stage I-III or IV (M1 LYM) esophageal cancer were 
treated with CRT. Median age of the patients was 68 years 
(range: 46 to 84); 76 were men and 10 were women. 
Histology was squamous cell carcinoma in 98%. Patients were 
divided into 4 groups according to the stage and operability; 
Group 1: stage I patients (n = 10); Group 2: stage II-III 
operable patients (n = 20); Group 3: stage II-III (non-T4) 
inoperable patients (n = 21); and Group 4: stage III-IV (T4/M1 
LYM) patients (n = 35). Chemotherapy protocols were either 
cisplatin (70 mg/m2) plus 5-FU (700 mg/m2 x 4 days) 
administered every 4 weeks or low-dose daily cisplatin (4 
mg/m2) and 5-FU (200 mg/m2). Radiation was given by 10-
MV X rays with a daily fraction of 1.8-2 Gy. Treatment 
volume included primary tumor plus regional lymph nodes. A 
total dose between 60 and 70 Gy was chosen depending on 
the treatment volume. Median radiation dose was 64 Gy 
(range: 50-70 Gy; 5 patients could not complete planned 
treatment). Failure was confirmed by pathology or findings of 
progressive disease on serial endoscopy and/or imaging 
studies. Overall survival (OS) and locoregional control (LC) 
rates were calculated by the Kaplan-Meier method. Toxicities 
were evaluated by the Common Terminology Criteria for 
Adverse Events version 4.0. 
 
Results: For all 86 patients, the 3-year LC and OS rates were 
65% and 29%, respectively; they were 100% and 100%, 
respectively, in Group 1, and 72% and 42%, respectively, in 
Group 2. The 2-year LC and OS were 53% and 14%, 
respectively, in Group 3, and 69% and 25%, respectively, in 
Group 4. Overall response rate was 78% (complete response 
in 31 and partial response in 36). Grade 3 or higher acute 
toxicities, mainly hematological, were observed in 37% of the 
patients and 10% experienced grade 3 or higher late 
toxicities. 
 
Conclusion: CRT with FP and 60-70 Gy of radiation appears to 
be tolerable for patients with esophageal cancer. Although 
outcome of this treatment in inoperable patients is not 
satisfactory, the 3-year LC of 100% for stage I patients and 
76% for stage II-III operable patients appear promising. 
Further investigation is warranted to clarify the optimal 
radiation dose in CRT for esophageal cancer. 
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Purpose or Objective: The objective of this study was to 
investigate the prognostic value of circulating lymphocyte 
level at the beginning of postoperative chemoradiotherapy 
(CRT) in pancreatic adenocarcinoma. 
 
Material and Methods: From 2007 to 2014, 41 patients 
treated with postoperative CRT were analyzed. The median 
dose of radiotherapy was 50.4 Gy (range, 45 – 59.4) and 
chemotherapy was administered after surgery. Absolute 
lymphocyte counts (ALC) was obtained from complete blood 
count tests performed prior to CRT. We analyzed blood 
lymphocyte count as well as clinical parameters to identify 
prognostic factor 
 
Results: With a median follow-up of 16.9 months, 32 patients 
had cancer recurrence and 28 died from the disease. The 
median overall survival (OS) and disease free survival (DFS) 
were 19.7 months and 9.8 months. The median OS of high 
postoperative ALC (>2.074 ×10³/ μL) group was significantly 
longer than that of the lower ALC group (32.0 months versus 
17.0 months, p = 0.007). In multivariate analysis, high 
postoperative ALC was a good prognostic factor for OS. 
(Hazard Ratio = 0.341, CI, 0.149 – 0.778, p = 0.011). High ALC 
at the beginning of postoperative CRT was also a prognostic 
factor for DFS in multivariate analysis (Hazard Ratio = 0.452, 
CI, 0.215 – 0.946, p = 0.035). 
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Conclusion: Postoperative ALC is a significant prognostic 
factor for resected pancreatic cancer patients. Postoperative 
immune status might help to predict survival outcome and to 
stratify group that is effective in CRT for resected pancreatic 
cancer. 
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Purpose or Objective: To investigate prognostic factors for 
overall survival (OS) in hepatocellular carcinoma (HCC) 
patients treated with external beam radiotherapy (RT) for 
lymph node (LN) metastasis. 
 
Material and Methods: Between 2004 and 2015, 105 HCC 
patients underwent palliative RT for LN metastasis. The 
median age was 60 years (range, 30–82). Biologically 
effective radiation doses of 39–75 Gy10 (median, 59.0 Gy10) 
were delivered. The median follow-up period was 5.7 
months. 
 
Results: The median OS was 5.8 months. On univariate 
analysis, young age, symptoms related to LN metastasis, poor 
performance status, Child-Pugh class B–C, uncontrolled 
intrahepatic disease, non-nodal distant metastasis (DM), 
multi-station LN metastasis, biologically effective dose <60 
Gy10, lack of local response to RT, and stable or increased 
post-RT alpha-fetoprotein levels compared to pre-RT levels 
were significant prognostic factors predicting poor OS (all 
p<0.05). On multivariate analysis among pre-RT factors, 
symptoms related to metastatic LNs (HR, 2.93), Child-Pugh 
class B–C (HR, 2.77), uncontrolled intrahepatic disease (HR, 
2.74), and non-nodal DM (HR, 1.62) were significant 
prognostic factors for poor OS (all p<0.05). Risk stratification 
in 4 groups by the number of risk factors had a significant 
predictive value for OS, with patients having 0, 1, 2, and 3–4 
risk factors demonstrating median OS intervals of 18.0, 11.7, 
5.7, and 3.0 months, respectively (p<0.001). 
 
Conclusion: Our risk stratification model can be used 
effectively in assessing the life expectancy of the HCC 
patient before initiating palliative RT for LN metastasis. 
Moreover, the presence of symptoms related to LN metastasis 
was shown to be the most powerful indicator of poor OS. 
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Purpose or Objective: Sarcopenia is a major hallmark of 
cancer cachexia and associated with increased treatment 
toxicity and worse overall survival in cancer patients. The 
aim of the study is to investigate the incidence and course of 
sarcopenia in patients undergoing curative trimodality 
therapy for locally advanced esophageal cancer and to 
correlate skeletal muscle mass with treatment complications 
during neoadjuvant treatment and surgery. 
 
Material and Methods: A subset of 31 patients treated in a 
prospective trial for locally advanced esophageal cancer with 
induction chemotherapy, neoadjuvant chemoradiation and 
surgical resection were identified at two institutions and 
clinical data was analyzed for treatment-related adverse 
events and consequent additional hospitalizations. Skeletal 
muscle mass was obtained by a second analysis of staging CTs 
before, during and after curative trimodality therapy and 
analyzed based on previously established threshold values for 
sarcopenia. 
 
Results: Fourteen patients (45%) were characterized as 
sarcopenic at the initial staging. Unplanned hospitalizations 
occurred significantly more frequently in sarcopenic patients 
(71% vs. 29%, p = 0.03) with a significantly longer total 
duration of hospital stay including postoperative stay (median 
33.5 vs. 21.3 days, p < 0.05). During neoadjuvant therapy 
with a median duration of 3.5 months, patients showed a 
statistically significant reduction of of skeletal muscle mass 
of 10.1% (p < 0.01) resulting in an increase in the prevalence 
of sarcopenia from 45% to 74%. 
 
Conclusion: CT-based assessment of sarcopenia demonstrates 
a significant decline of muscle mass during curative 
trimodality therapy for locally advanced esophageal cancer 
and can predict toxicity-related unplanned hospitalization. 
Based on these findings, CT-based measurement of muscle 
mass may serve as objective parameter to identify frail 
patients in need of intensified supportive therapy. 
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Purpose or Objective: Loco-regional recurrence of 
esophageal cancer (REC) after initial treatment remains a 
dominant cause of death. Treatment options for REC are 
limited. This study was realized to assess the survival and 
symptom relief after salvage radio(chemo)therapy for 
recurrent esophageal cancer. 
 
Material and Methods: Data from 259 patients from 3 centers 
were retrospectively reviewed to screen for eligible patients. 
194 patients were excluded because of following criteria: 1) 
no pathologically confirmed squamous cell carcinoma or 
adenocarcinoma; 2) distant metastasis; 3) no dose-volume 
histogram (DVH) data available; 4) salvage resection after 
REC; 5) Brachytherapy in the initial or current treatment. 
Between January 1998 to December 2014 sixty-five patients 
with REC after curative intended treatment (primary RCT or 
surgical resection with or without neoadjuvant 
radiochemotherapy) met our inclusion criteria 
retrospectively. The recurrence was diagnosed by computed 
tomography (CT) and/or upper gastrointestinal endoscopy. 
The initial treatment was as follows: surgical resection in 47 
patients (72%), neoadjuvant RCT (median 50,4Gy, range 45-
50,4Gy) plus surgery in 12 (19%) patients or definitive RCT 
(median 60Gy, range 50,4-64 Gy) in 6 patients (9%). The 
median time to recurrence from initial treatment was 16 
months (range 3-101 months). 
 
Results: Median follow-up time for surviving patients was 27 
months (5-150 months). The 1-year and 2-year survival rates 
were 58 ± 6% and 27 ± 6%, respectively. Subjective symptom 
relief was achieved in 25 of 34 symptomatic patients (74%). 
The most common toxicities were leukopenia, nausea, 
vomiting and gastritis. RT Doses ³ 50Gy and ECOG-PS (1-2 vs. 
3) associated with better median survival time (MST) and 
prognosis, respectively (p=0.003;p=0.001).  
 
Conclusion: Salvage radio(chemo)therapy for recurrent 
esophageal cancer is a reliable option in patients suffering 
from REC. In particular therapy of symptoms caused by the 
tumor can be managed by salvage-RCT. The toxicity is in an 
acceptable range. Long-term survival is possible in some 
patients. 
 
